Maryjane Farr

Maryjane Farr

Auto-generated profile, based on publicly available information

Maryjane Farr

Division of Cardiology, Department of Medicine; Division of Cardiology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
HCHannah Copeland
Hannah Copeland
IKIvan Knezevic
Ivan Knezevic
DBDavid A. A Baran
David A. A Baran
VRVivek Rao
Vivek Rao
MPMichael Pham
Michael Pham
SHShelley A. Hall
Shelley A. Hall

1 June 2013 in JACC: Heart Failure
Verified
Journal Article
Closed access
TKTomoko Sugiyama Kato
Tomoko Sugiyama Kato
JJJeffrey Jiang
Jeffrey Jiang
PSPaul Christian Schulze
Paul Christian Schulze
UJUlrich Jorde
Ulrich Jorde
NUNir Uriel
Nir Uriel
MFMaryjane Farr
Maryjane Farr

1 December 2018 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
LTLauren K. Truby
Lauren K. Truby
KTKoji Takeda
Koji Takeda
VTVeli K. Topkara
Veli K. Topkara
HTHiroo Takayama
Hiroo Takayama
AGA. Reshad Garan
A. Reshad Garan
MFMaryjane Farr
Maryjane Farr

2 June 2024 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JFJustin Fried
Justin Fried
MFMaryjane Farr
Maryjane Farr
MKManreet Kanwar
Manreet Kanwar
NUNir Uriel
Nir Uriel
JHJaime Hernandez-Montfort
Jaime Hernandez-Montfort
NKNavin K. Kapur
Navin K. Kapur

1 July 2015 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
MFMaryjane Farr
Maryjane Farr
JMJames Mitchell
James Mitchell
MLMatthew Lippel
Matthew Lippel
TKTomoko S. Kato
Tomoko S. Kato
ZJZhezhen Jin
Zhezhen Jin
PSP. Christian Schulze
P. Christian Schulze

18 September 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MPMarcus R. Pereira
Marcus R. Pereira
MAMeghan M. Aversa
Meghan M. Aversa
MFMaryjane A. Farr
Maryjane A. Farr
BMBenjamin A. Miko
Benjamin A. Miko
JAJustin G. Aaron
Justin G. Aaron
EVElizabeth C. Verna
Elizabeth C. Verna
The safety and efficacy of tocilizumab for the treatment severe respiratory symptoms due to COVID‐19 remain uncertain, in particular among solid organ transplant (SOT) recipients. Thus, we evaluated the clinical characteristics and outcomes of 29 hospitalized SOT recipients who received tocilizumab for severe COVID‐19, compared to a matched control group who did not. Among a total of 117 total SOT recipients hospitalized with COVID‐19, 29 (24.8%) received tocilizumab. 90‐day mortality was significantly higher among patients who received tocilizumab (41%) compared to those who did not (20%, p=0.03). When compared to control patients matched by age, hypertension, chronic kidney disease and administration of high dose corticosteroids, there was no significant difference in mortality (41% v. 28%, p=0.27), hospital discharge (52% v. 72%, p=0.26) or secondary infections (34% v. 24%, p=0.55). Among patients who received tocilizumab, there was also no difference in mortality based on level of oxygen support (intubated v. not intubated) at time of tocilizumab initiation. In this matched control cohort study, tocilizumab appeared to be safe but was not associated with decreased 90‐day mortality. Larger randomized studies are needed to identify whether there are subsets of SOT recipients who may benefit from tocilizumab for treatment of COVID‐19.